Stocktoria
Xenetic Biosciences, Inc. XBIO
Xenetic Biosciences, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436,942 | $17,066 | $0 | $7.6M | $3.0M |
| R&D expense | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M | $1.7M | $4.9M | $2.9M | $4.1M | $43.7M |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M | -$13.9M | -$12.9M | -$7.3M | -$3.6M | -$47.4M |
| Interest expense | — | — | — | — | — | — | — | — | $1,818 | $729,572 |
| Income tax | $0 | $0 | $0 | $0 | $0 | -$2.9M | $0 | $0 | $0 | $0 |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M | -$10.9M | -$12.8M | -$7.3M | -$3.6M | -$54.2M |
| EPS (diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | — | — | — | — | — |
| Operating cash flow | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M | -$4.3M | -$6.4M | -$6.5M | $1.5M | -$8.8M |
| Free cash flow | — | — | — | — | — | — | — | -$6.5M | $1.5M | -$8.8M |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M | $13.2M | $21.5M | $14.4M | $19.2M | $21.0M |
| Total liabilities | $968,025 | $894,263 | $809,585 | $1.1M | $1.4M | $963,971 | $4.3M | $4.5M | $4.9M | $4.8M |
| Shareholders' equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M | $12.2M | $17.2M | $9.9M | $14.3M | $16.2M |
Growth · year-over-year · Revenue CAGR -0.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +19.0% | -1.6% | +48.8% | +47.1% | +165.6% | +2460.3% | — | -100.0% | +152.8% | — |
| Free cash flow growth | — | — | — | — | — | — | — | -535.3% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.